These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

722 related items for PubMed ID: 22763244

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D, Kusamura S, Nonaka D, Langer M, Andreola S, Favaro M, Gavazzi C, Laterza B, Deraco M.
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [Abstract] [Full Text] [Related]

  • 5. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
    Sugarbaker PH.
    Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL.
    J Clin Oncol; 2012 Jul 10; 30(20):2449-56. PubMed ID: 22614976
    [Abstract] [Full Text] [Related]

  • 8. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy.
    Elias D, Gilly F, Quenet F, Bereder JM, Sidéris L, Mansvelt B, Lorimier G, Glehen O, Association Française de Chirurgie.
    Eur J Surg Oncol; 2010 May 10; 36(5):456-62. PubMed ID: 20227231
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution.
    Chua TC, Yan TD, Smigielski ME, Zhu KJ, Ng KM, Zhao J, Morris DL.
    Ann Surg Oncol; 2009 Jul 10; 16(7):1903-11. PubMed ID: 19387742
    [Abstract] [Full Text] [Related]

  • 11. Upfront compared to delayed cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei is associated with considerably lower perioperative morbidity and recurrence rate.
    Chua TC, Liauw W, Zhao J, Morris DL.
    Ann Surg; 2011 Apr 10; 253(4):769-73. PubMed ID: 21475018
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Elias D, Honoré C, Ciuchendéa R, Billard V, Raynard B, Lo Dico R, Dromain C, Duvillard P, Goéré D.
    Br J Surg; 2008 Sep 10; 95(9):1164-71. PubMed ID: 18690633
    [Abstract] [Full Text] [Related]

  • 16. Critical assessment of risk factors for complications after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei.
    Saxena A, Yan TD, Chua TC, Morris DL.
    Ann Surg Oncol; 2010 May 10; 17(5):1291-301. PubMed ID: 20039212
    [Abstract] [Full Text] [Related]

  • 17. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.
    El Halabi H, Gushchin V, Francis J, Athas N, Macdonald R, Nieroda C, Studeman K, Sardi A.
    Ann Surg Oncol; 2012 Jan 10; 19(1):110-4. PubMed ID: 21701929
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
    Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M.
    Ann Surg; 2009 Feb 10; 249(2):243-9. PubMed ID: 19212177
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.